Transcription
Oklahoma Central Cancer RegistryWeb Plus User ManualUpdated June 2022
Table of ContentsOklahoma Central Cancer Registry (OCCR) Staff . IVSection 1 .1Core instructions for Reporting Facilities .1Electronic Coding Manuals/Databases . 2Submission Schedule . 5Reportable Conditions List . 6Case-finding. 7Comprehensive ICD-10-CM Case-finding Code List for Reportable Tumors . 8Ambiguous Terminology for Determining Reportability . 11Differential Diagnosis . 12Laterality . 15List of Paired Organ Sites . 15Diagnostic Confirmation for Solid Tumors . 17Estimating Dates . 18Section 2 .27Web Plus Training Narrative .27Enter New Abstract . 28Hospital Specific . 28Reporting Facility: . 28Abstracted By: . 28*Date of 1st Contact: . 28Date 1stContact Flag: . 29Type of Reporting Source:. 29*Accession No: . 29*Sequence No: . 29*Class of Case: . 29Patient Information . 29*Name - Last: . 30*Name - First: . 30Name - Middle: . 30Name - Alias: . 30Name – Birth Surname: . 30Name - Suffix: . 30*Social Security No:. 30Medical Rec No: . 30Medicare Beneficiary ID: . 31*Date of Birth: . 31Date Birth Flag:. 31*Birthplace State: . 31*Birthplace Country: . 31*Sex: . 31*Race 1-5: . 31Page I
*Hispanic Ethnicity: . 32*Primary Payer at DX: . 32*Tobacco Use Smoking Status . 32Patient Address Information . 32*Number and Street at Diagnosis: . 32Supplemental Address at Diagnosis: . 32*City at Diagnosis . 32*State at Diagnosis:. 32*Zip Code at Diagnosis: . 33*County at Diagnosis: . 33TEXT - Usual Occupation: . 33TEXT - Usual Industry: . 33Cancer Information . 33*Date of Diagnosis: . 33Date Diagnosis Flag: . 33*Age at Diagnosis: . 33*Primary Site - Text: . 33*Primary Site: . 34TEXT - Primary Site: . 34*Laterality: . 34*Histologic Type: . 34*Behavior Code: . 34*TEXT - Histology: . 35*Diagnostic Confirmation: . 35*Grade Clinical: . 35*Grade Pathological: . 35*Grade Post Therapy Clinical (yc): . 35*Grade Post Therapy Path (yp): . 35*Regional Lymph Nodes Positive: . 35*Regional Lymph Nodes Examined: . 36Lymphovascular Invasion . 36Text – Diagnosis . 36*Physical Exam Text: . 36*X-ray/Scan--Text:. 36*Scopes--Text: . 37*Lab Tests Text:. 37*Operative report Text: . 37*Pathology--Text: . 37Place of Diagnosis--Text: . 38Stage of Disease . 38*Tumor Size Summary: . 38*Summary Stage 2018 . 38*Staging Text: . 38Site Specific Data Items . 38*Site Specific Data Items . 38Schema Discriminator 1 & 2:. 39Brain Molecular Markers: . 40Breslow Tumor Thickness . 40Page II
LDH Lab Value: . 40Esophagus and EGJ Tumor Epicenter:. 40Estrogen Receptor Summary . 40Progesterone Receptor Summary . 40HER2 Overall Summary . 40Fibrosis Score . 40Gleason Patterns Clinical . 41Gleason Patterns Pathological . 41Gleason Score Clinical . 41Gleason Score Pathological . 41Gleason Tertiary Pattern . 41PSA (Prostatic Specific Antigen) . 41Microsatellite Instability (MSI) . 41p16 . 41First Course of Treatment . 42*Diagnostic Procedure: . 42*Date Diagnostic Procedure: . 42Date DX Procedure Flag: . 42*TEXT - Surgery: . 42*Surgery Primary Site:. 42*Date--Surgery: . 42Date – Surgery Flag: . 42TEXT - Radiation (Beam). 43TEXT - Radiation Other . 43Phase I Radiation Treatment Modality . 43Date Radiation Started . 43Date Radiation Ended . 43Date Radiation Ended Flag . 43TEXT - Chemotherapy . 43Chemotherapy . 43Date Chemotherapy . 43Date Chemotherapy Flag . 43TEXT - Hormone Therapy . 44Hormone Therapy . 44Date Hormone Therapy . 44Date Hormone Therapy Flag . 44TEXT - Immunotherapy . 44Immunotherapy . 44Date Immunotherapy . 44Date Immunotherapy Flag . 44TEXT - Other Treatment . 44Other Treatment . 45Date Other Treatment . 45Date Other Treatment Flag . 45*Regional Lymph Node Surgery: . 45*Surgery of Other Regional/Distant Site: . 45Reason No Surgery: . 45Reason No Radiation: . 45Page III
Radiation/Surgery Sequence: . 45Systemic/Surgery Sequence:. 45Treatment Status: . 46First Treatment Date: . 46First Treatment Date Flag: . 46Treatment Date Most Definitive Surgery:. 46Treatment Date Most Definitive Surgery Flag: . 46Patient Outcomes. 46*DateLastContact/Death: . 46DateLastContact/DeathFlag: . 46*Vital Status: . 46Cause of Death: . 47ICD Revision Number: . 47Place of Death State: . 47Place of Death Country: . 47Treatment Referral Information . 47Physician Primary Surgery:. 47Physician/Referral/Remarks: . 47Date Case Completed:. 47EDIT Over-Ride Flags . 47Over-ride Age/Site/Morphology: . 47Over-ride Seq No/Dx Confirmation:. 48Over-ride Site/Lat/Seq No:. 48Over-ride Surg/Dx Conf: . 48Over-ride Site/Type: . 48Over-ride Histology: . 48Save Abstract and Run Data Edits . 48Section 3 .32Web Plus Training Manual for Facility Abstractors .32Introduction . 34Web Plus Features . 34Web Plus Users . 34Online Abstracting. 34Log In . 34Abstracting . 36Create a New Abstract . 37Changing Your Password . 39Web Plus Version Information . 39Logging Out . 40Adding Data to a Saved Abstract . 40Opening and Updating an Abstract. 40Print Preview . 42Correcting Edit Errors . 43Understanding Edit Sets . 43Edit Errors Tab . 43Completing and Releasing Abstracts. 43Completing the Abstract . 43Page IV
Releasing the Abstract . 44Correcting Errors in Released Cases . 45Page V
Oklahoma Central Cancer Registry (OCCR) StaffRaffaella Espinoza, MPHAnalytics & Dissemination ancer Surveillance CoordinatorChristy Dabbs, AA, CTRData pliance & Education SpecialistPaula Marshall, BBA, CTRQuality Assurance & Operations Specialistpaulam@health.ok.gov405-426-8014Judy Hanna, HT (ASCP), CTRPathology Laboratories Specialistjudyh@health.ok.gov405-426-8013Leslie DillAmbulatory Surgery Center/Dermatology Office Consultantleslied@health.ok.gov405-426-8017Lisa Fulkerson, RMAFacility Consultant, Large Hospitalslisaf@health.ok.gov405-426-8015Kerri Torgler, BSHIM, RHITFacility Consultant, Small cantTreatment Center/Physician Office Consultant405-426-8010405-426-8011405-426-8016Page IV
Section 1Core instructions forReporting FacilitiesPage 1
Electronic Coding Manuals/DatabasesInternational Classification of Diseases for Oncology (ICD-O) Manual, Third EditionUse: To determine applicable codes for primary site (topography), and histology (morphology).The ICD-O-3 book (purple book) has three main sections: topography, morphology and the alphabeticindex. There is also a brief listing of behavior codes and grades. The alphabetic index contains bothtopography and morphology codes which make it an excellent starting point when looking for key wordswithin a diagnosis or primary site. Codes in the alphabetic index can be looked up in the topography andmorphology sections for additional terms which qualify for a specific code.The World Health Organization (WHO) publishes the ICD-O manuals. There is updated content for ICD-O3.2 with an updated list of histology codes. The completion of a new manual has been delayed due to theCOVID-19 pandemic. However, there are instructions and spreadsheets listing the updates. All updates toICD-O terms and codes are issued through the North American Association of Central Cancer Registries(NAACCR). Abstractors should refer to the following updates to determine ICD-O codes.ICD-O-3.1Use for General Instructions and primary site codes only. Do not use this manual for histology codes sinceit is /96612ICD-O-3.2Effective January 1, 2022https://www.naaccr.org/icdo3/2022 ICD-O-3 Update to be used jointly with ICD-O-3.2, Solid Tumor Rules, and Hematopoietic andLymphoid Neoplasm DatabaseThe 2022 ICO-O-3.2 Upda
The ICD-O-3 book (purple book) has three main sections: topography, morphology and the alphabetic index. There is also a brief listing of behavior codes and grades. . Do not use the ICD-O tables to code hematopoietic or lymphoid neoplasms. Refer to the online Hematopoietic Database and Coding Manual for these cases. (Histology codes 9590/3 .
